肺腺癌伴癌性淋巴管炎的完全代谢缓解
本文报道一例右肺腺癌伴双肺广泛受累及癌性淋巴管炎的患者,基线18F-FDG PET/CT用于分期,后接受3周期卡铂联合培美曲塞方案化疗及口服塞瑞替尼,疗效评估时18F-FDG PET/CT显示完全代谢缓解及原发肺病灶显著缩小,属罕见现象。
要点
- 肺腺癌伴癌性淋巴管炎为不良预后标志。
- 基线18F-FDG PET/CT示双肺广泛受累及癌性淋巴管炎。
- 3周期卡铂联合培美曲塞及口服塞瑞替尼后达完全代谢缓解。
核心结论
- 肺腺癌伴癌性淋巴管炎患者经卡铂联合培美曲塞方案化疗及口服塞瑞替尼后,18F-FDG PET/CT评估显示完全代谢缓解及原发肺病灶显著缩小,属罕见现象。
研究设计与样本
- 本文为个案报道,描述一例右肺腺癌伴癌性淋巴管炎患者的诊治经过。
主要发现
- 基线18F-FDG PET/CT用于分期,显示双肺广泛受累及癌性淋巴管炎模式。
- 患者接受3周期卡铂联合培美曲塞方案化疗及口服塞瑞替尼。
- 疗效评估时18F-FDG PET/CT显示完全代谢缓解及原发肺病灶显著缩小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary lymphangitic carcinomatosis refers to the tumor spread into the lymphatic system of the lungs and is considered a poor prognostic marker. We present an interesting case of adenocarcinoma of right lung evaluated with 18 F-FDG PET/CT for baseline staging, with extensive bilateral lung involvement and lymphangitic carcinomatosis pattern. Subsequently, the patient received 3 cycles of carboplatin- and pemetrexed-based chemotherapy regimen along with oral ceritinib. Complete metabolic response and significant reduction in size of the primary lung lesion was noted on response evaluation with 18 F-FDG PET/CT, which is a rare phenomenon.
引用
- Goyal H, Kishore S, Ganesan P, et al. Complete Metabolic Response in Adenocarcinoma Lung With Lymphangitic Carcinomatosis. Clin Nucl Med. 2022. PMID: 36252925. doi:10.1097/RLU.0000000000004463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。